AbbVie to Invest $1.4 Billion in North Carolina Manufacturing Campus
By Elias Schisgall
AbbVie will invest $1.4 billion in a pharmaceutical-manufacturing campus in Durham, N.C.
The biopharmaceutical company said the 185-acre campus, near Research Triangle Park, would begin construction this year, with completion expected by the end of 2028.
The investment is part of AbbVie's commitment to put $100 billion toward manufacturing and research and development in the U.S. over 10 years. It is the company's first major investment in North Carolina.
"Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States," Chief Executive Officer Robert Michael said.
The campus will include advanced manufacturing and laboratory technologies leveraging artificial-intelligence, the company said. The initial phase of construction will focus on a warehouse, laboratories, and manufacturing facilities for small volume parenterals, or injectable pharmaceutical products with volumes less than 100 milliliters.
"When completed, this campus will serve as AbbVie's U.S. center of excellence for SVP manufacturing and deliver next-generation medicines to patients in the U.S. and worldwide," the company said.
The campus is expected to support 734 new hires over the next four years, as well as more than 2,000 construction jobs, AbbVie said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
April 22, 2026 12:43 ET (16:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
United States